We are live on ! Find out more
BTAI icon

BioXcel Therapeutics
BTAI

96 hedge funds and large institutions have $325M invested in BioXcel Therapeutics in 2023 Q1 according to their latest regulatory filings, with 23 funds opening new positions, 30 increasing their positions, 27 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

130% more first-time investments, than exits

New positions opened: 23 | Existing positions closed: 10

58% more call options, than puts

Call options by funds: $5.79M | Put options by funds: $3.67M

16% more funds holding

Funds holding: 83 → 96 (+13)

13% more capital invested

Capital invested by funds: $287M → $325M (+$37.6M)

11% more repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 27

0.75% more ownership

Funds ownership: 3% → 3.75% (+0.75%)

Holders
96
Holders Change
+13
Holders Change %
+15.66%
% of All Funds
1.53%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
23
Increased
30
Reduced
27
Closed
10
Calls
$5.79M
Puts
$3.67M
Net Calls
+$2.12M
Net Calls Change
+$264K

Top Buyers

Rank Fund Capital Flow
1
State Street
State Street
Massachusetts
+$37.2M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$35.6M
3
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$32.2M
4
Bank of America
Bank of America
North Carolina
+$5.99M
5
Two Sigma Investments
Two Sigma Investments
New York
+$5.82M

Top Sellers

Rank Fund Capital Flow
1
AIM
Artemis Investment Management
United Kingdom
-$9.4M
2
BPA
Beacon Pointe Advisors
California
-$6.49M
3
N
Nuveen
North Carolina
-$3.82M
4
DCM
Driehaus Capital Management
Illinois
-$3.13M
5
IC
Ikarian Capital
Texas
-$3.12M
Name Holding Trade Value Shares
Change 		Change in
Stake
AIP
76
Ameritas Investment Partners
Nebraska
$25.2K – – –
WTA
77
Washington Trust Advisors
Massachusetts
$23.3K – – –
MLICM
78
Metropolitan Life Insurance Company (MetLife)
New York
$18.9K -$8.11K -19 -23%
AAG
79
Armstrong Advisory Group
Massachusetts
$18.7K – – –
Fifth Third Bancorp
80
Fifth Third Bancorp
Ohio
$18.7K – – –
NA
81
NewEdge Advisors
Louisiana
$18.7K +$5.55K +13 +26%
QCG
82
Quadrant Capital Group
Ohio
$15.8K +$22.6K +53 New
Canada Life
83
Canada Life
Manitoba, Canada
$14K – – –
National Bank of Canada
84
National Bank of Canada
Quebec, Canada
$10.6K -$3.42K -8 -19%
Group One Trading
85
Group One Trading
Illinois
$7.28K -$796K -1,864 -99%
ASN
86
Advisory Services Network
Georgia
$7.13K – – –
Russell Investments Group
87
Russell Investments Group
United Kingdom
$3.88K +$5.55K +13 New
TWA
88
TCI Wealth Advisors
Arizona
$2.85K +$4.27K +10 New
SWM
89
Spire Wealth Management
Virginia
$2.44K – – –
FDCDDQ
90
Federation des caisses Desjardins du Quebec
Quebec, Canada
$2.11K – – –
Carson Wealth (CWM LLC)
91
Carson Wealth (CWM LLC)
Nebraska
$2K +$2.56K +6 New
AAS
92
Ameritas Advisory Services
Nebraska
$1.87K +$2.56K +6 New
HFS
93
Hantz Financial Services
Michigan
$1K – – –
US Bancorp
94
US Bancorp
Minnesota
$616 – – –
LC
95
Lindbrook Capital
California
$411 +$427 +1 New
DFCM
96
Dark Forest Capital Management
Puerto Rico
$37 – – –
BPA
97
Beacon Pointe Advisors
California
– -$6.49M -18,884 Closed
Vontobel Holding
98
Vontobel Holding
Switzerland
– -$1.32M -3,843 Closed
SAM
99
Sectoral Asset Management
Quebec, Canada
– -$1.31M -3,822 Closed
T. Rowe Price Associates
100
T. Rowe Price Associates
Maryland
– -$356K -1,036 Closed
1 2 3
4
5

BTAI Hedge Fund Activity: Q1 2023 in Review

96 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in BioXcel Therapeutics (BTAI) for Q1 2023, worth a combined $325M — up 13% from $287M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BTAI positions and 10 closed out — a net gain of 13 holders — while 30 added to existing stakes and 27 trimmed.

The largest buyer was State Street, adding an estimated $37.2M. The largest seller was Artemis Investment Management, cutting an estimated $9.4M.

  • 96 institutional investors held BioXcel Therapeutics (BTAI) as of Q1 2023, up from 83 in Q4 2022.
  • Funds reported $325M of BioXcel Therapeutics stock for Q1 2023, up 13% quarter-over-quarter.
  • 23 funds opened new BioXcel Therapeutics positions in Q1 2023 and 10 closed out, a net change of +13 holders.
  • The largest BioXcel Therapeutics buyer in Q1 2023 was State Street, an estimated $37.2M added.
  • The largest BioXcel Therapeutics seller in Q1 2023 was Artemis Investment Management, an estimated $9.4M sold.

Based on aggregated 13F filings for Q1 2023.